Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Express Scripts
Cantor Fitzgerald
McKesson
Julphar
Deloitte
Healthtrust
Accenture

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZAVESCA

« Back to Dashboard

Clinical Trials for Zavesca

Trial ID Title Status Sponsor Phase Summary
NCT00319046 Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease Completed Actelion Phase 3 Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.
NCT00418847 Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis Completed Actelion Phase 2 The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.
NCT00418847 Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis Completed The Hospital for Sick Children Phase 2 The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis.
NCT00517153 Miglustat in Niemann-Pick Type C Disease Completed Actelion Phase 2 This is a phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2:1 ratio to either treatment with miglustat or to a non-treatment group. Both groups will follow an identical visit schedule.
NCT00537602 Miglustat / OGT 918 in the Treatment of Cystic Fibrosis Terminated Actelion Phase 2 Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zavesca

Condition Name

Condition Name for Zavesca
Intervention Trials
Pompe Disease 2
Diarrhea 1
Niemann-Pick Type C Disease 1
Cystic Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zavesca
Intervention Trials
Gaucher Disease 2
Niemann-Pick Diseases 2
Niemann-Pick Disease, Type C 2
Niemann-Pick Disease, Type A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zavesca

Trials by Country

Trials by Country for Zavesca
Location Trials
United States 10
Taiwan 3
Canada 3
Spain 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zavesca
Location Trials
New York 2
District of Columbia 2
Florida 2
Georgia 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zavesca

Clinical Trial Phase

Clinical Trial Phase for Zavesca
Clinical Trial Phase Trials
Phase 3 3
Phase 2 3
Phase 1 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zavesca
Clinical Trial Phase Trials
Completed 6
Recruiting 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zavesca

Sponsor Name

Sponsor Name for Zavesca
Sponsor Trials
Actelion 7
National Taiwan University Hospital 2
University of Florida 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zavesca
Sponsor Trials
Industry 8
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Medtronic
UBS
Dow
Boehringer Ingelheim
Cerilliant
Chinese Patent Office
Teva
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.